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Background: Death receptor 6 (DR6) is highly expressed in the human brain: it has been shown to induce axon
pruning and neuron death via distinct caspases and to mediate axonal degeneration through binding to N-terminal
β amyloid precursor protein (N-APP).
Methods: We investigated the expression of DR6 during prenatal and postnatal development in human
hippocampus and temporal cortex by immunocytochemistry and Western blot analysis (118 normal human brain
specimens; 9 to 41 gestational weeks; 1 day to 7 months postnatally; 3 to 91 years). To investigate the role of N-
APP/DR6/caspase 6 pathway in the development of hippocampal Alzheimer’s disease (AD)-associated pathology,
we examined DR6 immunoreactivity (IR) in the developing hippocampus from patients with Down syndrome (DS;
48 brain specimens; 14 to 41 gestational weeks; 7 days to 8 months postnatally; 15 to 64 years) and in adults with
DS and AD.
Results: DR6 was highly expressed in human adult hippocampus and temporal cortex: we observed consistent
similar temporal and spatial expression in both control and DS brain. Western blot analysis of total homogenates of
temporal cortex and hippocampus showed developmental regulation of DR6. In the hippocampus, DR6 IR was first
apparent in the stratum lacunosum-moleculare at 16 weeks of gestation, followed by stratum oriens, radiatum,
pyramidale (CA1 to CA4) and molecular layer of the dentate gyrus between 21 and 23 gestational weeks, reaching
a pattern similar to adult hippocampus around birth. Increased DR6 expression in dystrophic neurites was detected
focally in a 15-year-old DS patient. Abnormal DR6 expression pattern, with increased expression within dystrophic
neurites in and around amyloid plaques was observed in adult DS patients with widespread AD-associated
neurodegeneration and was similar to the pattern observed in AD hippocampus. Double-labeling experiments
demonstrated the colocalization, in dystrophic neurites, of DR6 with APP. We also observed colocalization with
hyper-phosphorylated Tau and with caspase 6 (increased in hippocampus with AD pathology) in plaque-associated
dystrophic neurites and within the white matter.
Conclusions: These findings demonstrate a developmental regulation of DR6 in human hippocampus and suggest
an abnormal activation of the N-APP/DR6/caspase 6 pathway, which can contribute to initiation or progression of
hippocampal AD-associated pathology.
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Table 1 Cases included in this study
Age range Number of cases Sex (male/female)
Controls
9 to 20 GW 36 19/17
21 to 41 GW 43 24/19
1 to 6 days 6 2/4
2 weeks to 7 months 21 11/10
3 to 65 years 18; 3 stage II 7/11
Trauma
30 to 67 years 3 3/0
Down syndrome
14 to 20 GW 20 9/6 5 not
determined
21 to 41 GW 13 7/6
7 to 12 days 3 3
2 to 8 months 5 4/1
15 to 64 years 7; 3 stage V; 2 VI male
Alzheimer’s disease
77 to 90 years 6; 3 stage V; 3 VI 2/4
GW: gestational weeks; Braak Neurofibrillary Staging: Stage II-VI.
Iyer et al. Journal of Neurodevelopmental Disorders 2013, 5:10 Page 2 of 14
http://www.jneurodevdisorders.com/content/5/1/10Background
Death receptors (DRs) belong to the tumor necrosis factor
receptor superfamily and are known to induce apoptosis
(programmed cell death) via the intracellular portion of
the receptor referred to as the ‘death domain.’ [1-3]. A
growing body of evidence indicates that DRs may mediate
a variety of biological functions, including nonapoptotic
functions [1,4-7].
Tumor necrosis factor TNFRSF21 (death receptor 6,
DR6) is a relatively new member of the DR family, which
has been found to induce apoptosis when overexpressed
[8,9] (for review see [3,7]). Recently, Nikolaev and col-
leagues [10] reported that the N-terminal fragment of
amyloid precursor protein (N-APP) may act as a ligand
of DR6 and trigger axon pruning and neurodegeneration
via caspase 6, suggesting a role for this receptor in the
neurodegeneration observed in Alzheimer’s disease (AD;
for review see [11]). Interestingly, different signaling cas-
cades have been shown to be involved in degeneration of
the axon (caspase 6) and neuronal cell body (caspase 3)
[10,12]. Although there is still discussion about the
formation of the N-APP fragment [13,14] and the struc-
tural features of the potential DR6-APP signaling com-
plex [15,16], the identification of this APP-dependent
pathway involving DR6 highlights the potential role of
this receptor in specific types of disease-associated
axonal degeneration. In addition, recent studies suggest
additional physiological functions of DR6 during brain
development [5,6].
DR6 is expressed in most human tissues [7,8]. Interest-
ingly, DR6 mRNA expression is high in adult brain and
particularly enriched in regions like the hippocampus
that are vulnerable in AD [10]. The downstream DR6 ef-
fector, caspase 6, has been shown to be activated early in
AD and to be associated with mild cognitive impairment
[17-19]. However, the expression pattern and cellular
localization of DR6 protein during human brain devel-
opment remains uncharacterized.
In this study, we examined the expression of DR6 in the
developing human hippocampus and temporal cortex to
get a better insight into the role of this receptor in pre-
natal human brain development. In addition, we investi-
gated DR6 expression in the developing hippocampus of
patients with Down syndrome (DS) prior to establishment
of AD neurodegeneration and in DS patients with AD
pathology compared with age-matched control, and in
hippocampal specimens obtained from patients with
sporadic AD with severe, endstage pathology. Elucidation
of complex pathogenetic pathways characterizing the
earliest stage of the detrimental processes that result in
neurodegeneration represents an essential first step to-
wards a therapeutic intervention, which could be able to
block these pathological processes and, eventually, prevent
the onset of the disease in DS patients.Methods
Human material
The subjects included in this study were selected from
the databases of the Departments of Neuropathology
of the Academic Medical Center, University of Amsterdam
(in a project entitled ‘Pathways common to brain develop-
ment and aging: defining strategies for preventive therapy
and diagnostics’ approved by the Research Ethics Commit-
tee of the Academic Medical Center), and the Institute of
Neurology, Medical University of Vienna, Austria (in a pro-
ject approved by the Ethical Committee of the Medical
University of Vienna, entitled ‘Molecular neuropathologic
examinations of neurodegeneration-related proteins in
Down syndrome, Ek Nr. 1316/2012), from the NICHD
Brain and Tissue Bank for Developmental Disorders and
from the Netherlands Brain Bank. Informed consent was
obtained for the use of brain tissue and for access to med-
ical records for research purposes. Tissue was obtained and
used in a manner compliant with the Declaration of
Helsinki. We included brains of fetuses at different gesta-
tional ages (9 to 36 gestational weeks (GW)), neonates, and
children from control and DS patients (Table 1). Fetal brain
was obtained from spontaneous or medically induced
abortions with appropriate maternal written consent for
brain autopsy. Gestational ages were based on obstetric
data, fetal and brain weights and standard fetal anthropo-
metric measurements. We performed a careful histo-
logical and immunohistochemical analysis and evaluation
of clinical data (including genetic data, when available).
We excluded subjects with other chromosomopathies,
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postmortem autolysis, severe hypoxic or ischemic enceph-
alopathy, intraventricular hemorrhages, severe hydroceph-
alus, and meningitis or ventriculitis. Dyslamination in the
dentate gyrus was observed in one DS subject. As
controls, we only included brain specimens displaying a
normal hippocampal and cortical structure for the corre-
sponding age and without any significant brain pathology.
We did not use quantitative methods in this study to
evaluate gliosis or neuronal cells loss. We acknowledge
the limitations of visual inspection alone, which does not
accurately detect neuronal loss below approximately 30%
cell loss.
Additionally, we obtained adult brain tissue at autopsy
from eleven control subjects (without evidence of degen-
erative changes, and lacking a clinical history of cogni-
tive impairment), three patients with posttraumatic
brain injury, six patients with DS (Braak Neurofibrillary
Staging: V and VI), and nine patients with AD (three
with Braak stage II, without signs of cognitive impair-
ment and six with Braak stage V and VI) (Table 1). All
subjects were pathologically staged according to Braak
and Braak criteria [20]. Subjects without known cause of
death were excluded. All autopsies were performed
within 24 h after death.Tissue preparation
One or two representative paraffin blocks per brain
(hippocampus and temporal cortex) were sectioned,
stained, and assessed. Formalin-fixed, paraffin-embedded
tissue was sectioned at 6 μm and mounted on precoated
glass slides (Star Frost, Waldemar Knittel GmbH, Braun-
schweig, Germany). Sections of all specimens were
processed for hematoxylin eosin, Luxol fast blue, and
Nissl stains, as well as for immunocytochemical stains
for a number of markers, listed next. We performed a
silver impregnation (Bielschowsky) staining in all adult
brains.Immunocytochemistry
Glial fibrillary acidic protein (GFAP; polyclonal rabbit, DAKO,
Glostrup, Denmark; 1:4,000; monoclonal mouse; DAKO;
1:50), vimentin (mouse clone V9, DAKO; 1:400), neuronal
nuclear protein (NeuN; mouse clone MAB377, IgG1;
Chemicon, Temecula, CA, USA; 1:1,000), neurofilament pro-
tein (mouse clone 2 F11, Neomarkers, Fremont, CA, USA;
1: 200), synaptophysin (mouse clone Sy38; DAKO; 1:200;
polyclonal rabbit, DAKO; 1:200), human leukocyte antigen
(HLA)-DP, DQ, DR (major histocompatibility complex class
II, MHC-II; mouse clone CR3/43; DAKO, Glostrup,
Denmark, 1:400), and CD68 (mouse clone PG-M1, DAKO,
Glostrup, Denmark; 1:200) were used in the routine immuno-
cytochemical analysis.To detect death receptor 6 (DR6), we used a polyclonal
rabbit antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA; 1:100); to detect APP, a monoclonal antibody
(mouse clone 22C11, Chemicon, Temecula, CA, U.S.
A;1:50,000); and to detect caspase 6, a polyclonal rabbit
antibody (Abcam, Cambridge, MA, USA;1:500).
Single-label immunocytochemistry was developed using the
Powervision kit (Immunologic, Duiven, The Netherlands).
3,3-Diaminobenzidine (Sigma, St. Louis, USA) was used as
chromogen. Sections were counterstained with hematoxylin.
For double labeling of DR6 with amyloid-β (clone
M0872, DAKO; 1:200), GFAP, or synaptophysin, sections
were, after incubation with the primary antibodies over-
night at 4°C, incubated for 2 h at room temperature with
Alexa Fluor® 568-conjugated anti-rabbit and Alexa
Fluor®-conjugated 488 anti-mouse IgG or anti-goat IgG
(1:100, Molecular Probes, The Netherlands). Sections
were then analyzed using a laser scanning confocal
microscope (Leica TCS Sp2, Wetzlar, Germany).
For double labeling of DR6 with APP or Tau (Clone
AT8, Innogenetics Alpharetta, GA, USA; 1:5,000), or
caspase 6 or caspase 3 (polyclonal rabbit, Signaling
Technology Danvers, MA, USA; 1:100), sections were
incubated with Brightvision poly-alkaline phosphatase-
anti-rabbit (Immunologic, Duiven, The Netherlands) for
30 min at room temperature, and washed with PBS. Sec-
tions were washed with Tris–HCl buffer (0.1 M, pH 8.2)
to adjust the pH. Alkaline phosphatase activity was visu-
alized with the alkaline phosphatase substrate kit I
Vector Red (SK-5100, Vector laboratories Inc., CA,
USA). To remove the first primary antibody (DR6),
sections were incubated at 121°C in citrate buffer (10
mM NaCi, pH 6.0) for 10 min. Incubation with the sec-
ond primary antibody was performed overnight at 4°C.
Sections with primary antibody other than rabbit were in-
cubated with post antibody blocking from the Brightvision
+ system (containing rabbit-anti-mouse IgG; Immuno-
logic, Duiven, The Netherlands). Alkaline phosphatase
activity was visualized with the alkaline phosphatase sub-
strate kit III Vector Blue (SK-5300, Vector laboratories
Inc., CA, USA). Sections incubated without the primary
antibodies or with the primary antibodies, followed by
heating treatment were essentially blank. Images were an-
alyzed with a Nuance VIS-FL Multi-spectral Imaging Sys-
tem (Cambridge Research Instrumentation; Woburn,
MA), as described previously [21,22].
Evaluation of immunostaining
All labeled tissue sections were evaluated by two inde-
pendent observers, blind to clinical data, for the presence
or absence of various histopathological parameters and
specific immunoreactivity for the different markers. The
intensity of DR6 staining was evaluated, as previously de-
scribed [23,24], using a using a semi-quantitative scale
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strong; 4: very strong staining). Different sub-areas of the
hippocampus (CA1 to CA4 and dentate gyrus) were ex-
amined: the score represents the predominant intensity
found in each case.
We measured optical density in control and DS hippo-
campus (as previously described [25]) for DR6 in the
CA1. Sections were digitized using an Olympus micro-
scope equipped with a DP-10 digital camera (Olympus,
Japan). Images from consecutive, nonoverlapping, fields
(magnification, 20×) were collected using image acquisi-
tion and analysis software (Phase 3 Image System inte-
grated with Image Pro Plus; Media Cybernetics, Silver
Spring, MD). The absolute pixel staining density and the
background from fields lacking labeling was determined.
A mean optical density value for the CA1 was calculated,
expressed as a ratio with the mean optical density of the
background and comparison was made between patients.
Statistical analyses were performed with SPSS for Win-
dows (SPSS 11.5, SPSS Inc., Chicago, IL, USA). Data
were analyzed using a two-tailed Student’s t test or a
nonparametric Kruskal-Wallis test, followed by a Mann–
Whitney test to assess the difference between groups. A
value of P < 0.05 was defined statistically significant.
Western blot analysis
For immunoblot analysis we used frozen brain speci-
mens (control cortex: 13 to 41 GW; 1 day postnatally; 2
and 7 months postnatally; 3, 4, and 7 years; and adult
cortex (46, 50, 50 years); as well as control hippocampus:
19 GW; 2 months postnatally; 2 years; and adult hippo-
campus). The frozen specimens were homogenized in lysis
buffer containing 10 mM Tris (pH 8.0), 150 mM NaCl,
10% glycerol, 1% NP-40, 0.4 mg/ml Na orthovanadate, 5
mM EDTA (pH 8.0), 5 mM NaF, and protease inhibitors
(cocktail tablets, Roche Diagnostics, Mannheim, Germany).
Protein content was determined using the bicinchoninic
acid method [26]. For electrophoresis, equal amounts
of protein (50 μg/lane) were separated by sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) (10% acrylamide). Separated proteins were trans-
ferred to nitrocellulose paper by electroblotting for 1 h
and 30 min (BioRad, Transblot SD, Hercules, CA). After
blocking for 1 h in Tris-buffered saline with Tween
(TBST; 20 mM Tris, 150 mM NaCl, 1% Tween, pH 7.5)/
5% nonfat dry milk, blots were incubated overnight at 4°C
with rabbit anti-DR6 (1:1,000), mouse anti-β-tubulin
(1:30,000, monoclonal mouse, Sigma, St. Louis, MO, USA),
or APP (1:50,000). After several washes in TBST, the
membranes were incubated in TBST and 5% nonfat dry
milk, containing the goat anti-rabbit or rabbit anti-
mouse coupled to horse radish peroxidase (1:2,500; Dako,
Denmark) for 1 h. After washing in TBST, immunoreactiv-
ity was visualized using ECL PLUS Western blottingdetection reagent (GE Healthcare Europe, Diegen,
Belgium). To quantify the blots, band intensities were
measured densitometrically using Scion Image for
Windows (beta 4.02) image-analysis software. A ratio
of the integrated band density (IntDen) of the protein
of interest to the IntDen of the reference protein was
used to normalize band intensities.
Results
Developmental expression of DR6 in control
hippocampus and cerebral cortex
The expression pattern of DR6 was studied immunocyto-
chemically at different prenatal ages, ranging from 10 to
40 GW, as well as at postnatal ages (1 day to 7 months
and 3 to 8 years; Figure 1; Additional file 1: Figure S2). At
the earliest stages of development evaluated (9 to 15 GW),
DR6 expression in the hippocampus and cortical plate
was below the level of detection (Figure 1A-B; Table 2).
Weakly reactive fibers were, however, detected in the
subplate at 13 to 15 GW (Figure 1D). In the hippocampus,
DR6 IR was first apparent in the stratum lacunosum-
moleculare at 16 GW, followed by the stratum oriens,
radiatum, pyramidale (CA1 to CA4) and the molecular
layer of the dentate gyrus between 21 and 25 GW
(Figure 1C-F; Table 2). During this developmental
period, an increase in DR6 IR was also detected in the
neocortex, reaching a pattern similar to adult hippo-
campus around birth (Figure 1I). From 40 weeks to
term, the entire hippocampal complex displayed
prominent IR, with a pattern similar to that observed
in adult hippocampus (Figure 1G-H; Additional file 2:
Figure S1; Figure 2A). The IR pattern was similar in
young adults (<40 years) compared with older control
subjects (>50 years).
Western blot analysis could only be performed where
frozen temporal cortex and hippocampus material was
available (Figure 3). As previously reported [27], DR6 re-
ceptor protein was detected as a band of approximately 75
kDa, consistent with the predicted size from DR6 cDNA.
Expression of DR6 in the temporal cortex (Figure 3) and
hippocampus (not shown) was detected at all ages exam-
ined; however, its expression increased postnatally in the
cortex, reaching adult levels by about 1 year of age.
Developmental expression of DR6 in Down syndrome
hippocampus and cerebral cortex
In DS brains, the DR6 pattern of IR in both fetal hippo-
campus and neocortex was similar to that observed in
age-matched controls (Figure 2A-B; Figure 4; Table 2).
Only weakly reactive fibers were detected in the cortical
subplate at 13 to 15 GW (Figure 4A). Between 21 and
35 GW the DR6 IR increased progressively in the neo-
cortex (Figure 4D; 35 GW), reaching a pattern similar to
that observed in adult hippocampus around birth (not
Figure 1 (See legend on next page.)
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the SLM at 16 GW, followed by the stratum oriens,
radiatum, pyramidale (CA1 to CA4), and molecular layer
of the dentate gyrus between 21 and 35 GW (Figure 4B-C;
Table 2). From 40 weeks to term, prominent IR wasobserved throughout the different hippocampal subfields
with a pattern similar to that detected at postnatal ages
(Figure 4E-G; Figure 2A). Increased DR6 expression
was occasionally detected in dystrophic neurites in a
15-year-old DS patient (Figure 4H). The immunoreactivity
(See figure on previous page.)
Figure 1 DR6 immunoreactivity (IR) at different gestational ages (13, 17, 23, 25 gestational weeks, GW) and at 1 day postnatally. A-B:
13 GW. A: the hippocampus shows no detectable DR6 IR. B: the cerebral cortex shows weakly reactive fibers in the subplate zone (SP, arrows;
high magnification in insert), but no reactivity in the cortical plate (CP), intermediate zone (IZ) or ventricular zone (VZ). C-D: 17 GW. C: light DR6
IR is detected in the hippocampus in the stratum lacunosum-moleculare (SLM). D: cerebral cortex shows no reactivity in the CP. E (23 GW) and F
(25 GW) show evident DR6 IR in the different hippocampal subfields (stratum oriens, SO; stratum pyramidale, SP; stratum lacunosum-moleculare,
SLM; molecular layer dentate gyrus, ML). G-J: 1 day. G: strong DR6 IR is observed throughout the different hippocampal subfields; high
magnification of CA3 and CA1 is shown in H and I, respectively. J: Diffuse and strong DR6 IR is observed throughout the neocortex. Dentate
gyrus, DG; granule cell layer, gcl; stratum lucidum, SL. Hematoxylin counterstain shows blue nuclei. Scale bar (shown in J): A, C-G, 400 μm; B, 200
μm; H-I, 40 μm; J, 80 μm.
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CA1) of fetal and infant DS samples were similar to age-
matched controls (Figure 2A-B). Colocalization was ob-
served with synaptophysin; we did not observe colocalization
with GFAP (data not shown).Expression pattern of DR6 in DS with AD pathology
In adult hippocampus of 50 to 64-year-old DS, the pres-
ence of AD pathology was associated with an abnormal
pattern of DR6 IR (Figure 5). Strong DR6 IR was
detected in dystrophic neurites in and around amyloid
plaques (Figure 5C-D). Although the immunoreactive
score of adult hippocampus was similar to controls
(Figure 2A), the ODR in the CA1 was higher in DS
with AD pathology than in age-matched controls (Figure 2B).
Evaluation of APP IR during hippocampal development
showed increased IR in CA1 neurons prior to establishment
of AD pathology (Additional file 1: Figure S2A-B). By
Western blot analysis, a major band corresponding to
the mature ~130 kDa isoform was identified at all ages
examined (not shown). In DS brains with AD path-
ology, prominent increase of APP IR was detected
throughout the hippocampus (Additional file 1: Figure
S2C; Figure 5E). DR6 IR colocalized with APP and
hyperphosphorylated Tau in plaque-associated dystrophic
neurites but not with the β-amyloid core (Figure 5F-H).Table 2 Summary of DR6 immunoreactivity in human
fetal hippocampus in control and Down syndrome
Hippocampal complex Onset staining Onset staining
Control (GW) Down syndrome
(GW)
Stratum lacunosum-moleculare 16 16
Stratum oriens 21 21








Stratum lucidum 40 41
GW: gestational week.Occasionally, DR6 IR was detected in dystrophic neurites
in elderly patients (Braak stage II), without cognitive decline
(not shown). The pattern of DR6 IR in the hippocampus of
AD patients (Braak stage V-VI) was similar to that observed
in DS with AD pathology (Additional file 3: Figure S3), with
strong DR6 IR in dystrophic neurites in and around amyloid
plaques (Additional file 3: Figure S3 B-D) and colocalization
with APP and hyperphosphorylated Tau (Additional file 3:
Figure S3 E-H). Spectral analysis of double labeling of DR6
with hyperphosphorylated Tau or with APP confirmed the
colocalization in both AD and DS adult hippocampus
(Additional file 4: Figure S4).Expression pattern of caspase 6 in DS with AD pathology:
colocalization with DR6
In adult hippocampus of 50 to 64-year-old DS with AD
pathology we observed prominent upregulation of caspase 6
IR throughout the hippocampus with strong expression in
neuritic plaques and neurofibrillary tangles (Figure 6C-F).
Caspase 6 IR colocalized with DR6 and APP in plaque-
associated dystrophic neurites (Figure 6G-H); we did not ob-
serve colocalization of DR6 with caspase 3. Spectral analysis
of double labeling of caspase 6 with APP and DR6 confirm
colocalization in DS adult hippocampus with AD pathology
(Figure 7), and in AD hippocampus (not shown).Discussion
Increasing evidence supports the concept that neuro-
logical disorders of the adult brain could represent a dis-
order of aberrant neural development. According to this
‘developmental hypothesis,’ even neurodegenerative disor-
ders might have ‘fetal’ origins (for reviews see [11,28,29]).
Recent studies have provided evidence of a physio-
logical function for N-APP in developmental pruning,
which, together with other mechanisms, could also con-
tribute to neurodegeneration in AD (for review see [11]).
In particular, it has been suggested that activation of
DR6 is required for initiation or progression of axonal
degeneration [10]. However, the expression pattern and
cellular localization of DR6 protein in developing brain
is still largely uncharacterized and it is not clear whether,
or to what extent, the N-APP-DR6 pathway might be ab-









































9-15 gw 16-20 gw 21-25 gw 26-41 gw 1-15 d 2-8 m 1-15 yrs a
9-15 gw 16-20 gw 21-25 gw 26-41 gw 1-15 d 2-8 m 1-15 yrs adult
Control
DS
Figure 2 Evaluation of DR6 immunoreactivity in hippocampus of control and Down syndrome (DS) during development. A:
immunoreactive score (IR) for DR6 in the hippocampus (CA1 to CA4 and dentate gyrus) B: relative optical density ratio (ODR) of DR6
immunoreactivity in CA1. Values represent the mean ± SEM of samples at different prenatal and postnatal ages. *P < 0.05, compared with control.
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sion pattern and cellular localization of DR6 in human
hippocampus and neocortex during the pre- and early
postnatal development. The period of prenatal develop-
ment studied (9 to 40 GW) includes all the critical stages
of human hippocampal and cortical development [30-32].
Developmental regulation of DR6 expression was ob-
served in both neocortex and hippocampus by immuno-
cytochemistry and was confirmed by Western blot
analysis, revealing relatively high expression levels in
adult brain tissue. In agreement with previous observa-
tions at the mRNA level [10], DR6 was particularlyenriched in the hippocampus. DR6 IR was already de-
tectable in the SLM at 16 GW and prominent IR was
observed throughout the different hippocampal subfields
by 40 GW. The expression of DR6 during the prenatal
stages of hippocampal development supports the sug-
gested physiological role of this receptor in shaping
neuronal connections, in particular contributing to
axonal pruning (for review see [11]), which deserves fur-
ther investigation in experimental models.
An attractive hypothesis, provided by in vitro and
in vivo studies using DR6 knockout mice, is that acti-
vation of DR6 by N-APP may, via caspase 6, contribute
Figure 3 Western blot analysis of DR6 in total homogenates of temporal cortex at different gestational ages. A: representative blot of
DR6 (≈75 kDa) in total homogenates of 13, 23, 25, 40 gestational weeks (GW) cortex, 2, 7 months, and 7 years postnatally and in adult temporal
cortex. B: densitometric analysis. For each sample, the optical density of the DR6 was calculated relative to the optical density of the reference
protein β-tubulin and expressed as percentage of adult control (mean ± SEM of three samples from 13, 14, 15, 17, 22, 23, 25 GW cortex, and
control adult cortex). C: representative blot of DR6 and β-tubulin in total homogenates of 19 GW, 2 months, 2 years, and adult hippocampus.
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the N-APP/DR6/caspase 6 pathway is abnormally acti-
vated in AD and whether its activation might precede
the development of AD, we studied the components of
this pathway in DS hippocampus. AD-associated
neuropathology is a consistent feature in DS patients
and DS represents an opportunity to understand the
link between early aging and neurodegenerative pro-
cesses [33,34]. Immunocytochemical evaluation of APP
(using an antibody that recognizes N-APP) provided
evidence of expression prior to establishment of AD
pathology. In addition, an increased expression of DR6
in dystrophic neurites (similarly to cases of early AD
pathology; Braak stage II) was detected in a 15-year-old DS
patient. Detection of a premature neuritic pathology in DS
is consistent with previous evidence supporting the occur-
rence of ongoing neurodegeneration prior to the establish-
ment of widespread AD neurodegeneration [35-38]. In adult
DS cases with frank dementia as well as significant AD path-
ology, caspase 6 expression was strongly increased within
the hippocampus. Interestingly, we detected colocalization
of DR6 and caspase 6 (as well as hyperphosphorylated Tau
and APP) in plaque-associated dystrophic neurites.These observations support the possible involvement
of the N-APP/DR6/caspase 6 pathway in the develop-
ment and progression of AD-associated pathology in
DS patients. Accordingly, a similar aberrant pattern of
DR6 expression was detected in sporadic AD cases
with severe, endstage pathology. The presence of ab-
normal DR6 expression within the white matter sug-
gests that there is also a role of this pathway in the
development of white matter abnormality reported in
DS brain [38,39]. In particular, a recent study [39] sug-
gests that myelination is impaired in DS hippocampus.
Interestingly, a role for DR6 signaling in oligodendro-
cyte maturation and myelination has recently been
suggested [5,40,41]. Thus, although we did not ob-
served detectable difference in the expression pattern
of DR6 in DS patients without AD pathology, the role
of DR6 in the delayed myelination in DS hippocampus
requires further evaluation.
Immunocytochemical studies of postmortem fetal tis-
sue represent one of the few available approaches for
studying protein expression during human brain de-
velopment, providing information about their temporal
and spatial distribution that can be used to interpret
Figure 4 DR6 immunoreactivity (IR) at different gestational ages (14, 17, 35, 40 gestational weeks, GW) in Down syndrome. A 14 GW:
the cerebral cortex shows weakly reactive fibers in the subplate zone (SP, arrows; high magnification in insert), but no reactivity in the cortical
plate (CP), intermediate zone (IZ), or ventricular zone (VZ). B 17 GW: light DR6 IR is detected in the hippocampus in the stratum lacunosum-
moleculare (SLM; DG, dentate gyrus). C-D (35 GW): DR6 IR is observed throughout the different hippocampal subfields (C) and in the neocortex
(D). E-F 40 GW: strong DR6 IR is observed in the different hippocampal subfields (high magnification of CA1 is shown in F). G-H 15 years: with
DR6 IR throughout the different hippocampal subfields and focal accumulation of IR in dystrophic neurites in the CA1 (arrows in H). Hematoxylin
counterstain shows blue nuclei. Scale bar (shown in H): A, 200 μm; B, C, E, G, 400 μm; D, F, 40 μm; H, 20 μm.
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Figure 5 DR6 immunoreactivity (IR) in control and Down syndrome (DS) adult hippocampus. A-B: adult hippocampus of control (A) and DS (B),
showing DR6 IR throughout the different hippocampal subfields (DG, dentate gyrus). C, D: high magnification of CA1 (C) and DG (D) in DS showing
strong DR6 expression in dystrophic neurites in amyloid plaques (arrows). E: amyloid precursor protein (APP) IR is detected in the dystrophic neurites of
plaques (arrows) in DS. F: colocalization of APP and DR6 in dystrophic neurites (purple; arrows) in DS. G: localization of hyperphosphorylated Tau and
DR6 in dystrophic neurites (purple; arrows and insert) in DS. H: Confocal image showing accumulation of DR6 IR (red) around β-amyloid deposits (green)
in DS. Hematoxylin counterstain shows blue nuclei (A-E). Scale bar (shown in H): A-B, 400 μm; C-E, 80 μm; F-H, 40 μm.
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Figure 6 Caspase 6 (Casp6) immunoreactivity (IR) in controls and Down syndrome (DS) adult hippocampus. A-B: control hippocampus
(B, CA1) without detectable Casp6 IR, without accumulation in neurons. C-F: DS hippocampus showing increased Casp6 IR throughout the
hippocampus; D-F show high magnification of CA1 with strong IR in tangles (arrows in E), neuropil threads, and dystrophic neurites in plaques
(arrowheads in E and arrows in F). G: colocalization of Casp6 and APP in dystrophic neurites (purple; arrows and insert). H: colocalization of Casp6
and DR6 in dystrophic neurites (purple; arrows and insert). Hematoxylin counterstain shows blue nuclei (A-F). Scale bar (shown in H):
A,C, 400 μm; B, D, 160 μm; E, 80 μm; F, 40 μm. G-H, 25 μm.
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Figure 7 Spectral analysis of double labeling of caspase 6 (Casp6) with Amyloid precursor protein (APP) or DR6 in Down syndrome
(DS) adult hippocampus. A-C: double labeling of Casp6 with APP. A: light microscopical image of the original immunostained section showing
Casp6 in blue and APP in red. B, C: spectral analysis of the same section showing double stained structures in purple (arrows in B) and in yellow
(arrows in C). D-H: double labeling of Casp6 with DR6. D, G: light microscopical image of the original immunostained section showing Casp6 in
blue and DR6 in red. E, F, H: spectral analysis showing double stained structures in purple (arrows in E and H) and in yellow (arrow in F). Scale bar
(shown in H): A-C, 80 μm; D-F, 40 μm; G-H, 20 μm.
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these studies is the availability of brain tissue. An ideal
experimental design (including postnatal ages ranging
between 10 and 40 years of age, prior to the establish-
ment of widespread AD neurodegeneration) is difficult
to achieve, and frozen representative material is not
available at all developmental ages. Another important
aspect that should be taken into consideration when
analyzing DS brain is that individuals with DS develop
dementia with clinical and neuropathologic features
similar, but not identical, to those of adults with AD
without DS (that is including complex developmental
abnormalities) [42-45]. Moreover, it has been suggested
that oxidative stress and inflammation present early
events in DS brain pathology [35].
An important issue that requires clarification is repre-
sented by the still discussed mechanism of formation of N-
APP fragment and its physiological role in human brain.
Guo and co-authors [14] argue in their study that APPβ
and total APP are both highly stable. Other recent studies
report that APP can be processed by the metalloprotease
meprin β, resulting in specific N-APP fragments, which,however, did not exert significant cytotoxicity [13,46].
Moreover, recently, a novel amyloid precursor protein-
processing pathway that generates secreted N-terminal
fragments has been described [47].
Our study cannot resolve these complex issues; however,
it provides evidence of strong DR6 expression in human
hippocampus with increased IR in dystrophic neurites in
DS brains in parallel with the evolution of AD-associated
lesions. The detection of increased DR6 expression before
endstage AD pathology and dementia are established sug-
gests that this aberrantly increased expression of DR6
could represent an early marker of AD neuronal degener-
ation. Thus, premature activation of DR6 may contribute
to accelerate the formation of dystrophic neurites and
more extensive AD pathology through apoptosis mecha-
nisms. However, axonal degeneration might occur via
multiple pathways, which can converge on a common
downstream target. Recently, a nicotinamide mononucleo-
tide adenylyltransferase 1-sensitive pathway has been de-
scribed [12]. Moreover, a novel apoptotic pathway that
mediates the DR6 apoptotic signal to mitochondrial dys-
function has been reported. [9].
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Our findings demonstrate a developmental regulation of
DR6 in human hippocampus and highlight the potential
role of DR6 in specific types of disease-associated neur-
onal degeneration. Thus, future investigation targeting
DR6 in experimental models might be worthwhile to
further develop our current understanding of the role of
DR6 signaling pathways in the initiation or progression
of hippocampal AD-associated pathology.
Additional files
Additional file 1: Figure S2. β amyloid precursor protein (APP)
immunoreactivity (IR) at different ages in Down syndrome (DS)
hippocampus. A-B: DS hippocampus (35 GW and 8 months) showing
focal accumulation in CA1 neurons at 35 GW (insert in A) and 8 months
(insert in B). C: adult DS hippocampus with prominent increase of APP IR
throughout the hippocampus; insert in C shows accumulation in
dystrophic neurites. Hematoxylin counterstain shows blue nuclei. Scale
bar (shown in C): A-C, 400 μm.
Additional file 2: Figure S1. DR6 immunoreactivity (IR) postnatally (2
weeks, 5 months). A, C: hippocampus (2 weeks, A and 5 months, C),
showing strong DR6 IR throughout the different hippocampal subfields. B,
D: neocortex (2 weeks, B and 5 months, D), showing diffuse and strong DR6
IR throughout the cortex. Hematoxylin counterstain shows blue nuclei.
Stratum lacunosum-moleculare, SLM; Molecular layer–dentate gyrus, ML;
dentate gyrus, DG. Scale bar (shown in D): A-C, 400 μm; D, 80 μm.
Additional file 3: Figure S3. DR6 immunoreactivity (IR) in Alzheimer’s
disease (AD). A-D: AD (stages VI) showing DR6 IR throughout the
different hippocampal subfields (A) and strong DR6 expression in
dystrophic neurites in CA1 (B, D arrows and insert in B) and white matter
(C). E-F: colocalization (purple; arrows) of amyloid precursor protein (APP;
blue) and DR6 (red) in dystrophic neuritis. G-H: colocalization (purple;
arrows) of hyperphosphorylated Tau (blue) and DR6 (red) in dystrophic
neurites (purple; arrows), but not in neurons containing neurofibrillary
tangles (arrowhead and insert in H). Hematoxylin counterstain shows
blue nuclei (A-D). Scale bar (shown in H): A, 400 μm; B, 160 μm; D, E,
40 μm; C, F-H, 30 μm.
Additional file 4: Figure S4. Spectral analysis of double labeling of DR6
with hyperphosphorylated Tau or with β amyloid precursor protein (APP)
in Alzheimer’s disease (AD) and Down syndrome (DS) adult
hippocampus. A-C: double labeling of DR6 with APP in AD. A: light
microscopical image of the original immunostained section showing DR6
in red and APP in blue. B and C: spectral analysis of the same section
showing double stained structures in purple (arrows in B) and in yellow
(arrows in C). D-F: double labeling of DR6 with Tau in AD. D: light
microscopical image of the original immunostained section showing DR6
in red and Tau in blue. E and F: spectral analysis of the same section
showing double stained structures in purple (arrows in E) and in yellow
(arrows in F). G-H: double labeling of DR6 with APP in DS. G: light
microscopical image of the original immunostained section showing DR6
in red and APP in blue. H: spectral analysis of the same section showing
double stained structures in yellow (arrows). I-J: double labeling of DR6
with Tau in DS. I: light microscopical image of the original
immunostained section showing DR6 in red and Tau in blue. J: spectral
analysis of the same section showing double stained structures in yellow
(arrows). Scale bar (shown in J): A-F, 80 μm; G-J, 40 μm.
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